VGX-100 / Opthea - LARVOL DELTA

"GX88, VGX3100, DNA vaccines for cervical cancer" (@aLwOmbaT)

Clinical • Cervical Cancer • Oncology • Solid Tumor

"#Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100 $REGN" (@DelawareHere)

Infectious Disease

"#Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100" (@JPPerry11)

Infectious Disease

Circadian commences first phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients (Circadian) - Circadian Technologies has commenced the first P1 trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre; Study will examine the safety & tolerability of escalating doses of VGX-100 in pts with adv solid tumours who have no other standard treatment options both as a monotherapy & also when used in combination with other anti-angiogenic agents; Results are expected in H2 2012

Anticipated P1 data • P1 trial initiation • Oncology

"INO has a drug in phase 3 VGX3100 for cervical dysplasia, a precancer. Do you have any opinions on this drug?" (@richard_diggler)

P3 data

"My favorite beaten up biotech stock to make huge gains in 19 is $INO. @InovioPharma Fantastic partnerships with @MedImmune @genentech @Regeneron @parkerici @CEPIvaccines @niaid @TheWistar @DARPA #HIV #catalysts very close w/100% safety profile in all trials. closely #vgx3100" (@pquirke100)

Clinical • Licensing / partnership